These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 9045912)

  • 1. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K; Bonardelle D; Bobé P; Kiger N
    Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse.
    Zhou T; Bluethmann H; Eldridge J; Berry K; Mountz JD
    J Immunol; 1993 Apr; 150(8 Pt 1):3651-67. PubMed ID: 7682246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D; Benihoud K; Kiger N; Bobé P
    J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
    Williams NS; Engelhard VH
    J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of the protein kinase C-dependent apoptosis pathway in distinct subsets of T lymphocytes in MRL-lpr/lpr mice.
    Ohkusu K; Isobe K; Hidaka H; Nakashima I
    Eur J Immunol; 1995 Nov; 25(11):3180-6. PubMed ID: 7489761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine-insensitive partial signaling and multiple roles of Ca2+ in Fas ligand-induced lysis.
    Rogers AM; Thilenius AR; Russell JH
    J Immunol; 1997 Oct; 159(7):3140-7. PubMed ID: 9317111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS; Engelhard VH
    J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
    Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
    J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
    J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of alternative or concomitant use of perforin- and Fas-dependent pathways in a T cell-mediated negative regulation of Ig production.
    Majlessi L; Bordenave G
    J Immunol; 1999 Apr; 162(8):4391-8. PubMed ID: 10201974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
    Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
    J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
    Lowin B; Hahne M; Mattmann C; Tschopp J
    Nature; 1994 Aug; 370(6491):650-2. PubMed ID: 7520535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of immune responses by CD8 cells. I. Superantigen-activated CD8 cells induce unidirectional Fas-mediated apoptosis of antigen-activated CD4 cells.
    Noble A; Pestano GA; Cantor H
    J Immunol; 1998 Jan; 160(2):559-65. PubMed ID: 9551888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veto activity of activated bone marrow does not require perforin and Fas ligand.
    Chrobak P; Gress RE
    Cell Immunol; 2001 Mar; 208(2):80-7. PubMed ID: 11333140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.